Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $56.00

Cogent Biosciences (NASDAQ:COGT) had its price target increased by HC Wainwright from $55.00 to $56.00 in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the technology company’s stock. HC Wainwright also issued estimates for Cogent Biosciences’ Q4 2026 earnings at ($0.67) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at $0.19 EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($1.09) EPS.

A number of other equities analysts have also issued reports on COGT. Wedbush reissued an “outperform” rating and set a $55.00 price target on shares of Cogent Biosciences in a research report on Wednesday, September 16th. Guggenheim upped their price objective on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, October 2nd. Wall Street Zen lowered shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Piper Sandler raised their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $53.57.

Cogent Biosciences Stock Down 7.1%

Cogent Biosciences stock opened at $29.40 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 13.57 and a current ratio of 10.99. The business’s 50-day simple moving average is $31.63 and its two-hundred day simple moving average is $35.41. The company has a market cap of $5.12 billion, a PE ratio of -13.07 and a beta of 0.36. Cogent Biosciences has a fifty-two week low of $27.74 and a fifty-two week high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Thursday, November 5th. The technology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). Equities analysts anticipate that Cogent Biosciences will post -2.28 EPS for the current year.

Institutional Trading of Cogent Biosciences

Hedge funds have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Cogent Biosciences by 26.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 209,402 shares of the technology company’s stock valued at $8,104,000 after acquiring an additional 43,892 shares in the last quarter. Sculptor Capital LP purchased a new stake in Cogent Biosciences in the 2nd quarter worth approximately $1,935,000. Wellington Management Group LLP boosted its position in Cogent Biosciences by 21.4% in the 2nd quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company’s stock worth $168,112,000 after purchasing an additional 765,355 shares in the last quarter. Legal & General Group Plc purchased a new stake in Cogent Biosciences in the 2nd quarter worth approximately $3,824,000. Finally, SEB Asset Management AB acquired a new stake in shares of Cogent Biosciences during the 1st quarter worth approximately $6,329,000.

Top Cogent Biosciences Stories

Investors following COGT have been watching these stories:

• Positive Sentiment: A separate report said COGT shares moved above their 50-day moving average, a potentially supportive technical signal. Share-price technical report
• Neutral Sentiment: Coverage describes analysts’ views as conflicting, indicating that optimism is not uniform. Analyst sentiment coverage
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 and Q1 2027 EPS estimates, and the company’s latest reported quarterly loss of $0.59 per share was wider than the $0.56 consensus estimate. Those near-term pressures may weigh against the more upbeat 2027 outlook. Estimate revisions

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.